Serina Therapeutics, Inc. Balance Sheet
SER|7 years of annual SEC 10-K data (FY2018-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 7 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Total Assets
$7M
FY2025
Cash
$3M
Cash and equivalents
Total Debt
N/A
FY2025
Shareholder Equity
-$37,000
FY2025
Serina Therapeutics, Inc. had $7M in total assets with negative shareholders' equity of $37,000 as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 1/9 criteria passed
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2018 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.1M | $3.7M | $7.6M | $645.0K | $584.0K | $2.4M | $6.7M |
| Accounts Receivable | - | - | $57.0K | $4.0K | $25.0K | $326.0K | $131.0K |
| Current Assets | $6.1M | $5.7M | $7.6M | $2.5M | $2.2M | $2.3M | $7.9M |
| PP&E (Net) | $465.0K | $501.0K | $573.0K | - | - | - | $90.0K |
| Total Assets | $7.0M | $6.7M | $9.0M | $3.2M | $3.2M | $3.9M | $10.7M |
| Current Liabilities | $3.6M | $2.4M | $1.4M | $10.1M | $9.0M | $5.4M | - |
| Total Debt | - | - | - | $18.1M | $13.2M | - | - |
| Shareholders' Equity | -$37.0K | $641.0K | -$32.3M | -$17.2M | -$11.8M | -$5.1M | $7.4M |